Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

July 09, 2026 22:14 ET | Source: MindRank AI Ltd.

MindRank Announces $52 Million Series B Financing

Funding to advance AI-native drug R&D engine and pipelines, including MDR-001, an oral GLP-1 small-molecule in Phase III clinical trials in China.
July 07, 2026 07:35 ET | Source: Vivani Medical, Inc.

Vivani Medical Enters into Agreement with Novo Nordisk to Evaluate NPM-139, a Miniature, Ultra Long-Acting Semaglutide Implant for Chronic Weight Management

Vivani Medical entered into agreement with Novo Nordisk to evaluate its miniature subdermal semaglutide (GLP-1) implant for weight management
July 07, 2026 07:00 ET | Source: Kailera Therapeutics, Inc.

Kailera Therapeutics Announces Positive Topline Data from Two Hengrui Pharma Phase 3 Clinical Trials of Oral Small Molecule GLP-1 Receptor Agonist HRS-7535/KAI-7535

Kailera Therapeutics Announces Positive Topline Data from Two Hengrui Pharma Phase 3 Clinical Trials of Oral Small Molecule GLP-1 Receptor Agonist HRS-7535
July 03, 2026 04:30 ET | Source: Custom Market Insights

[Latest] Global Antidiabetic Drugs Market Size/Share Worth USD 309.84 Billion by 2035 at a 11.62% CAGR: Healthcare Foresights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)

Austin, TX, USA, July 03, 2026 (GLOBE NEWSWIRE) -- Healthcare Foresights has published a new research report titled “Antidiabetic Drugs Market Size, Trends, and Insights By Drug Class (Insulin,...
July 01, 2026 09:05 ET | Source: Biotech Insider

A Nasdaq-Listed Regenerative Tissue Company Just Opened a Lab: The Next Step in Scaling a Platform Built for a NEW Aesthetics Opportunity

Issued on behalf of Conexeu Sciences Inc. Conexeu Sciences Inc. (NASDAQ: CNXU) opened a new research and development facility at adMare BioInnovations’ M4 Innovation Centre, expanding the home of...
July 01, 2026 07:30 ET | Source: PMGC Holdings Inc.

NorthStrive Biosciences Announces Positive Results from Phase III of AI-Driven Drug Discovery Program with Yuva Biosciences

NorthStrive Biosciences Announces Positive Results from Phase III of AI-Driven Drug Discovery Program with Yuva Biosciences
June 30, 2026 08:00 ET | Source: WW International Inc.

Weight Watchers Med+ Establishes Access to GLP-1s Through Medicare GLP-1 Bridge Program

NEW YORK, June 30, 2026 (GLOBE NEWSWIRE) -- WW International, Inc. (NASDAQ: WW) (“Weight Watchers”), the global leader in science-backed weight health, today announced that Weight Watchers Med+ will...
June 29, 2026 07:30 ET | Source: Kailera Therapeutics, Inc.

Kailera Therapeutics Appoints Kathleen Tregoning as Chief Corporate Affairs Officer

Kailera Therapeutics, Inc., a clinical-stage biotechnology company focused on elevating the next era of obesity care, today announced the appointment of Ka
June 29, 2026 05:00 ET | Source: Resalis Therapeutics SRL

Resalis Announces Initiation of Phase 1b Clinical Study Evaluating RES-010 as Treatment to Address Unmet Needs in Obesity

Torino, Italy, June 29, 2026 – Resalis Therapeutics today announced the dosing of the first participant in a Phase 1b clinical study of its lead candidate, RES-010, a novel antisense oligonucleotide...
June 25, 2026 09:04 ET | Source: Biotech Insider

The Aesthetics Giants Just Confirmed “Ozempic Face” Is Real — and a Newly Public Regenerative Player Wants to Compete for It

Issued on behalf of Conexeu Sciences Inc. With Galderma now presenting clinical data on treating medication-driven facial volume loss, the GLP-1 aesthetics category has gone mainstream — and...